Altimmune to Join Two Investor Conferences in May 2024

Altimmune, Inc., a clinical-stage biopharmaceutical firm based in Gaithersburg, Maryland, announced its participation in upcoming investor conferences. The company, which trades on Nasdaq under the symbol ALT, will have its management team available for one-on-one meetings at these events. 

The first event is the JMP Life Sciences Conference, taking place in New York, NY on Tuesday, May 14, 2024. During this conference, Altimmune will host a Fireside Chat scheduled for 9:00 a.m. Eastern Time. The second event is the UBS Obesity Therapeutics Day, a virtual conference set for Thursday, May 23, 2024. The Fireside Chat for this event is planned for 10:00 a.m. Eastern Time.

These sessions will be webcast, and interested parties can view them by visiting the Events section of the Altimmune website. This provides a platform for investors and other stakeholders to gain insights directly from the company's management.

Altimmune is dedicated to advancing its innovative peptide-based therapeutics. The company's primary focus is on developing pemvidutide, a dual receptor agonist targeting GLP-1 and glucagon receptors, intended for the treatment of obesity and non-alcoholic steatohepatitis (NASH). This dual-action approach is designed to address these significant health issues more effectively.

Altimmune's commitment to innovation is evident in its ongoing research and development efforts. The company aims to bring next-generation treatments to market, addressing unmet medical needs and improving patient outcomes.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!